AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03655496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based tool
Description: The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
Study NCT03641300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Description: MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
Study NCT03641300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Description: In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
Study NCT00840658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive injection and sexual risk intervention
Description: This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
Study NCT00840658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Sexual Risk Intervention
Description: This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
Study NCT03843242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with IRSplus algorithm on
Description: 1. After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~2. In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~3. The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm.
Study NCT00655135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDP-02
Description: Each patient in arms 2 \& 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
Study NCT00655135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
Study NCT02008240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle aspiration of hydrosalpinx
Description: Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
Study NCT02008240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
Study NCT03553017 — intervention group
Intervention type: DEVICE
Intervention: Binocular OCT
Description: Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
Study NCT04029532 — intervention group
Intervention type: DEVICE
Intervention: Respiratory exchange ratio
Description: Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
Study NCT04029532 — intervention group
Intervention type: DEVICE
Intervention: Heart rate variability
Description: Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
Study NCT04029532 — intervention group
Intervention type: DEVICE
Intervention: Body composition
Description: Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
Study NCT04029532 — intervention group
Intervention type: BEHAVIORAL
Intervention: Eating behavior
Description: Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
Study NCT02208323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Description: Respiratory assistance
Study NCT00061360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG+Rapamune+cyclosporine
Description: ATG+Rapamune+cyclosporine
Study NCT00061360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG+cyclosporine
Description: ATG+cyclosporine
Study NCT03930966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PDEQ, PCL-5 and demographic survey
Description: Questionnaires
Study NCT03110328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3475
Description: anti-PD1 immunotherapy
Study NCT04466332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeCath-CT PICC easy™ (Vygon)
Description: ECG electrodes are placed on patient's chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify a suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The PICC is advanced into the central circulation and used as an intracavitary electrode (connection with Vygocard2™). Saline water instilled through the catheter ensures conductivity.~The ECG is then used until displayed intracavitary P-wave has a maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The PICC hub side is then trimmed and the catheter part connected. The PICC is caped with a neutral bidirectional valve.~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess the position.
Study NCT04466332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerPICC-SOLO® (C.R. Bard)
Description: ECG electrodes are placed on patients chest ensuring that there is a distinguishable P-wave.~Upper arm selection is based on vein diameter and dominance, ultrasound is used to identify suitable vein.~The patient is prepared using a maximal sterile barrier approach. The catheter is inserted into one of the veins (75-90° arm abduction) using ultrasound and modified Seldinger technique.~The catheter's free end is cut to the anticipated length using anthropometric measurements (insertion/axillary crease+axillary crease/sternal notch+13cm) and the preloaded magnetic-tipped stylet (serving as intracavitary electrode) is put inside.~The PICC is advanced into central veins until intravascular ECG displays a P-wave with maximal height without negative deflexion. Catheter is left at this point (cavo atrial junction).~The puncture site is dressed and catheter stabilized. Chest Xray is obtained immediately after insertion to assess position.
Study NCT01062984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Venovenous Hemofiltration (CVVH)
Description: The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVH; the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
Study NCT01062984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Venovenous Hemodialysis (CVVHD)
Description: The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
Study NCT03205020 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum amyloid a test
Description: * Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~* Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~* The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University
Study NCT01151982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention
Description: The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources.
Study NCT02004860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protopic (R)
Description: Protopic® 0.1% ointment - 2 applications per week for 6 months
Study NCT02004860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycoster (R)
Description: Mycoster 1% - 2 applications per week for 6 months
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhitongluo Capsule
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naoxintong Capsule
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Study NCT01762163 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the routine recovery training
Study NCT01762163 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: the routine recovery training
Study NCT01762163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the routine recovery training
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01762163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT04029532 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity recall
Description: Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
Study NCT04029532 — intervention group
Intervention type: BEHAVIORAL
Intervention: Depression
Description: Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
Study NCT04029532 — intervention group
Intervention type: BEHAVIORAL
Intervention: Body image
Description: Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
Study NCT02381860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
Study NCT02381860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 60mL tart Montmorency cherry juice
Description: One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
Study NCT03433092 — intervention group
Intervention type: OTHER
Intervention: serum carotenoids
Description: In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
Study NCT04331730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKST4290
Description: Oral AKST4290
Study NCT04331730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study NCT04331730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept intravitreal injection
Study NCT04331730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept intravitreal injection
Study NCT00891657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SprayShield™
Description: Anti-adhesion barrier
Study NCT02743637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDX-7320
Description: SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
Study NCT03488823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: with Flavanol
Description: Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
Study NCT02112604 — intervention group
Intervention type: DEVICE
Intervention: Ventilator
Description: Mechanical ventilator used to replace or assist spontaneous breathing.
Study NCT02112604 — intervention group
Intervention type: DEVICE
Intervention: Alice PDx
Description: Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
Study NCT02112604 — intervention group
Intervention type: OTHER
Intervention: Pulmonary function test
Description: The pulmonary function tests are used to study upper airway patency.
Study NCT02112604 — intervention group
Intervention type: OTHER
Intervention: Muscle strength tests
Description: MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
Study NCT02112604 — intervention group
Intervention type: OTHER
Intervention: Grip strength measurement
Description: Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
Study NCT02112604 — intervention group
Intervention type: DRUG
Intervention: Sedatives and muscle relaxants given in the ICU
Description: Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
Study NCT01378754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol (Lusedra®) 6.5
Description: Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Study NCT01378754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol (Lusedra®) 10
Description: Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Study NCT01378754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol (Lusedra®) 12
Description: Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
Study NCT01258829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive haemodynamic optimisation
Description: Comparing the method of non-invasive haemodynamic
Study NCT01258829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECHO optimisation
Description: Standard ECHO optimisation method
Study NCT04575350 — intervention group
Intervention type: GENETIC
Intervention: reinterpretation of CNV
Description: Reinterpretation of CNV of unknown significance
Study NCT04138667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex decongestive therapy
Description: Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
Study NCT01212328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordinator + Decision Support Software
Description: Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
Study NCT01212328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
Study NCT02813330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcutaneous sterile water injection
Description: sterile water injection in two points of low back pain
Study NCT02813330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline injection
Description: Saline injection in two points of low back pain
Study NCT02812030 — intervention group
Intervention type: OTHER
Intervention: National Eye Institute Visual Functioning Questionnaire
Description: Routine treatment plus visual functioning questionnaires
Study NCT01716260 — intervention group
Intervention type: DRUG
Intervention: Chloroquine
Study NCT01716260 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Study NCT02890771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing with Dentifrice
Description: Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
Study NCT02890771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Turmeric Massaging
Description: :-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
Study NCT02890771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric Massaging
Description: :-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
Study NCT02890771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP with turmeric massaging
Description: on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
Study NCT02890771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP with turmeric massaging
Description: on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects